Knowledge of HIV Antibody Status and Decisions to Continue or Terminate Pregnancy Among Intravenous Drug Users

Peter A. Selwyn, Rosalind J. Carter, Ellie E. Schoenbaum, Verna J. Robertson, Robert S. Klein, Martha F. Rogers

Research output: Contribution to journalArticlepeer-review

117 Scopus citations

Abstract

We studied decisions to continue or terminate pregnancy among human immunodeficiency virus (HIV)-seropositive ( + ) and -seronegative (-) intravenous drug users informed of HIV antibody status before 24 weeks’ gestation. Fourteen (50%) of 28 HIV+ vs 16 (44%) of 36 HIV- women chose to terminate their pregnancies. In retrospective interviews, HIV + women were more likely to have perceived their risk of perinatal HIV transmission to be greater than or equal to 50% and, among those who terminated pregnancy, to cite this concern as an important factor in their decision. However, decisions to terminate pregnancy were predicted more readily by pregnancy-related variables such as prior elective abortion, a negative emotional reaction to pregnancy, and whether the pregnancy had been unplanned. Women who were HIV + and chose to continue their pregnancies cited the desire for a child, religious beliefs, and family pressure as the most important factors in their decisions. Results indicate that while concerns about perinatal transmission of HIV may lead to decisions to terminate pregnancy in certain cases, there may be other determinants of pregnancy decisions in this population. Counseling of HIV-infected women must address not only perinatal transmission but also the sociocultural and behavioral context in which pregnancy decision making takes place.

Original languageEnglish (US)
Pages (from-to)3567-3571
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume261
Issue number24
DOIs
StatePublished - Jun 23 1989

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Knowledge of HIV Antibody Status and Decisions to Continue or Terminate Pregnancy Among Intravenous Drug Users'. Together they form a unique fingerprint.

Cite this